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a b s t r a c t
Ethnopharmacological relevance: Lafoensia pacari A. St.-Hil. (Lythraceae), known popularly as “pacari” or
“mangaba-brava” is popularly used in the state of Goiás, Brazil. The stem bark or leaves are used to treat
cancer, gastric disorders, inﬂammation and as a tonic to treat loss of enthusiasm.
Aim of the study: Previous results suggest that the ethanol:water 7:3 extract of the stem bark of L. pacari
(PEx) has antidepressant-like activity in male mice. Our aim was to perform the PEx's bioguided
fractionation and evaluate the monoaminergic system involvement in the antidepressant effect as well as
progress in the study of L. pacari mechanism of action.
Material and methods: Mice (30–35 g) orally treated (24, 5 and 1 h) with PEx (100, 300 or 1000 mg/kg),
chloroform (ChloF—70 mg/kg), ethyl acetate (180 mg/kg), n-butanol (370 mg/kg) and aqueous (1 g/kg)
fractions were submitted to the forced swimming test. To assess the mechanism of action, different
groups of mice were pretreated with p-chlorophenylalanine (PCPA—100 mg/kg, 4 days, i.p.) and alpha-
methyl-p-tyrosine (AMPT—100 mg/kg, 4 h, i.p.) to assess the involvement of serotoninergic and
catecholaminergic systems in the ChloF effects, respectively. A putative in vitro inhibition of monoamine
oxidase (MAO) activity as well as the ex vivo hippocampal brain-derived neurotrophic factor (BDNF)
quantiﬁcation were carried out. Phytochemical screening, spectroscopy and chromatography analysis
were used for identiﬁcation of compounds present in ChloF.
Results and discussion: After the fractionation, the ChloF 70 mg/kg was the most active fraction, reducing
the immobility time by 22%. Pre-treatments with both PCPA and AMPT abolished the ChloF effects,
suggesting that ChloF antidepressant-like effect is dependent on serotonergic and catecholaminergic
systems. ChloF did not inhibited MAO-A or MAO-B activity, excluding this as possible mechanism of
action. ChloF augmented hippocampal BDNF level, which could be accounted for its antidepressant-like
effect. Phytochemical screening showed the presence of saponins, tannins, steroids and triterpene in the
PEx, and the presence of triterpene and steroids in ChloF. The spectroscopy and chromatography analysis
identiﬁed lupeol, β-sitosterol and stigmasterol in ChloF.
Conclusion: ChloF is the fraction that better retained the crude extract active constituents. ChloF presents
antidepressant-like effect that involves both serotonergic and catecholaminergic systems without
inhibiting MAO enzymatic activity; this fraction also increases the hippocampal BDNF levels.
& 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The use of plants as medicines for humankind is connected to
its own development. In Brazil, the traditional medicine is a rich
mixture of various cultures, mainly African (mostly Yoruba and
Bantu), European (mainly Portuguese), and Native South America
medical traditions (Sá and Elisabetsky, 2012). Among the many
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plants used in folk medicine by the population of the states of
Goiás and Mato Grosso, it is the herbal Lafoensia pacari A. St. Hil.
(Lythraceae family).
Lafoensia pacari is a tree plant of up to 5 m height that grows in
Brazilian Cerrado and altitude forest ecosystems being also present
in Paraguay and Bolivia (Silva, 1998). It is known popularly as
“pacari” which in Tupi-Guarani Amerindian language means
“precious wood”, but has other popular names, among them is
“mangaba-brava” (Proença et al., 2000). It has the botanical
synonyms Lafoensia sessilifolia Klotzch and L. pacari Saint-Hilaire
ssp. petiolata Koehne (Carvalho, 1994; Lorenzi, 2002).
In folk medicine, the L. pacari stem bark or leaves are widely
used after decoction in water or maceration in alcoholic drinks
such as “cachaça” or white wine (known as “garrafada”). This
medicinal plant is used to treat gastric ulcers, wounds, pain, local
and systemic inﬂammation, cancer, itch, diarrhea, kidney pro-
blems, besides being used as antipyretic, slimming, healing and, of
the special interest to us, as a tonic for the loss of energy (Cabral
and Pasa, 2009; Corrêa, 1984; Pott and Pott, 1994).
The literature has shown the pharmacologic potential of this
plant. Different extracts from this plant has shown antimicrobial
(Lima et al., 2006; Müller et al., 2007; Pereira et al., 2011; Silva
et al., 2010; Queiroz-Silva et al., 2012), antinociceptive (Guimarães
et al., 2010; Matos et al., 2008; Nascimento et al., 2011), anti-
inﬂammatory and anti-pyretic (Guimarães et al., 2010; Matos
et al., 2008; Rogerio et al., 2006, 2008), besides gastroprotective
(Menezes et al., 2006, Tamashiro-Filho et al., 2012) effects and
antioxidant and anti-cancer activities (Solon et al., 2000).
Our group have studied the L. pacari central effects in rodent
behavioral models, where we showed that the stem bark crude
ethanol:water 7:3 extract has anxiolytic-like activity (Galdino et al.,
2010); and when administered for 21 days by oral route, the PEx has
antidepressant-like effect (Galdino et al., 2009). Depressive disorders
are among the most prevalent lifetime mood disorders, affecting
approximately 16% of North Americans (Kessler et al., 2005) and
18.4% of Brazilians (Bromet et al., 2011). In this context, our aim was
to evaluate the involvement of monoaminergic system in the
antidepressant effect of the active fraction and phytochemically
characterize the extract and its active fraction.
2. Material and methods
2.1. Animals
Experiments were conducted using male Swiss mice, weighing
30–35 g, provided by the Central Animal House of Federal Uni-
versity of Goiás (Universidade Federal de Goiás—UFG). Animals
were maintained at constant room temperature of 21–23 1C with
free access to water and food, under a 12:12 h light:dark cycle
(lights on at 7:00 h). Animals were acclimatized for 4 days before
the beginning of the experiments. All experimental protocols were
developed in accordance with the principles of ethics and animal
welfare designated by Brazilian Society of Science of Laboratory
Animals (Sociedade Brasileira de Ciência em Animais de Labora-
tório—SBCAL) and the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health. All the
protocols were approved by the Ethics Commission of the UFG
(Protocol number 104/08). All behavioral experiments were con-
ducted from 1:00 p.m. to 5:00 p.m.
2.2. Plant material
The stem bark of L. pacari was collected (May 2011) from plants
in natural habitat in the savannah region of Bela Vista, Goiás, Brazil
(837 m, 16158054.2″ S, 40155045.1″ W). Samples were authenticated
by Prof. Dr. José Realino de Paula, and a voucher specimen was
deposited at the Herbarium of the Federal University of Goiás
(UFG) under the number 27031/UFG.
2.3. Extraction and fractionation
The stem bark was cut into small pieces, dried at 40 1C for 48 h,
powdered and stored under refrigeration until its use in the
extractive process. The stem bark maceration in alcoholic drinks
is the form widely used by Goiás population, then the pacari
ethanol:water 7:3 extract (PEx) was obtained by maceration in 70%
(v/v) hydro-alcoholic solution for 72 h, followed by ﬁltration and
evaporation in rotary evaporator (yield¼16.1%, w/w). Part of the
PEx (20 g) was dried and dissolved in 400 mL of methanol/water
solution (1:9), and successively partitioned with chloroform, ethyl
acetate and n-butanol. The yields of the chloroformic (ChloF), ethyl
acetate (EAF), n-butanol (BuF) and aqueous (AqF) fractions were 3,
9, 18 and 61% (w/w), respectively. ChloF were suspended in Tween
80s 2% (w/w) such as all other treatments (PEx, EAF, BuF and AqF).
2.4. Drugs
Clorgyline, pargyline, p-chlorophenylalanine (PCPA), α-methyl
para-tyrosine (AMPT), tyramine, vanillic acid, 4-aminoantipyrine,
peroxidase, polyoxyethylenesorbitan monooleate (Tween 80s)
were purchased from Sigma-Aldrich (Brazil). Imipramine (Trofa-
nils—Novartis, Brazil), ﬂuoxetine (EMS, Brazil). PCPA, AMPT was
suspended in a 0.9 w/v% NaCl solution containing 2% Tween 80 for
oral treatment. Imipramine and ﬂuoxetine were dissolved in a
0.9 w/v% NaCl solution for oral treatment.
2.5. Methods
2.5.1. Extract, fraction and drugs effects on open ﬁeld test (OFT)
In order to investigate the PEx effects in locomotor activity in
male mice, animals (n¼10–12) were treated (p.o) with vehicle
(Tween 80s 2%) 10 mL/kg, PEx 100, 300 and 1000 mg/kg or
imipramine 30 mg/kg (positive control). The same animal received
the same treatment by gavage at the times of 24, 5 and 1 h before
the open ﬁeld test. In the bio-guided fractionation, animals (n¼9)
were treated (p.o.) with vehicle, ChloF 70 mg/kg, EAF 180 mg/kg,
BuF 370 mg/kg, AqF 1 g/kg or imipramine 30 mg/kg (positive
control) (24, 5 and 1 h) before the OFT. In a separate series of
experiments, to assay the ChloF dose-effect curve, animals (n¼9–
11) were treated (p.o.) with vehicle, ChloF 35, 70 and 140 mg/kg or
imipramine 30 mg/kg (positive control) (24, 5 and 1 h) before the
OFT. To avoid possible false-positive results due to alteration in
animal's ambulation in the mechanism of action study; the mice
(n¼8–11) pretreated (i.p.) with PCPA (100 mg/kg, a tryptophan
hydroxylase inhibitor) or vehicle (2% Tween 80), once a day, for
4 consecutive days; in addition, the animal were orally treated
with vehicle or ChloF 70 mg/kg (24, 5 and 1 h) and submitted to
the OFT. The animals (n¼8–11) pretreated (i.p.) with AMPT
(100 mg/kg, a tyrosine hydroxylase inhibitor) or vehicle (2% Tween
80) 4 h, and after treated (p.o.) with vehicle or ChloF 70 mg/kg (24,
5 and 1 h) were also submitted to the OFT. The apparatus consisted
of a circular arena measuring 36 (diameter)20 cm (height), with
the bottom divided into eight equal areas. Animals were indivi-
dually placed at the center of the open ﬁeld arena and allowed to
explore it for 5 min (Archer, 1973). During this time, the locomotor
activity: deﬁned as the number of total squares crossed/5 min, was
videotaped. The arena was cleaned with a 10% ethanol solution
after each animal.
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2.5.2. Crude extract and fractions antidepressant-like effect
In order to investigate the PEx antidepressant-like effect in
male mice, animals (n¼10–12) were treated (p.o) with vehicle
(Tween 80s 2%) 10 mL/kg, PEx 100, 300 and 1000 mg/kg or
imipramine 30 mg/kg (positive control). The same animal received
the same treatment by gavage at the times of 24, 5 and 1 h and
immediately after the OFT the animals were submitted to the
forced swimming test (FST). In the bioguided fractionation, ani-
mals (n¼9) were treated (p.o.) with vehicle, ChloF 70 mg/kg, EAF
180 mg/kg, BuF 370 mg/kg, AqF 1 g/kg or imipramine 30 mg/kg
(positive control) (24, 5 and 1 h) before the OFT followed by the
FST. In a separate series of experiments, to assay the ChloF dose-
effect curve, animals (n¼9–11) were treated (p.o.) with vehicle,
ChloF 35, 70 and 140 mg/kg or imipramine 30 mg/kg (positive
control) (24, 5 and 1 h) before the OFT followed by the FST. Other
group of animals that received the same treatments was evaluated
in tail suspension test (TST) to conﬁrm the ChloF antidepressant-
like effect. In the FST, each mouse was individually placed in a
plastic cylinder (diameter 18 cm, height 42 cm) ﬁlled with water at
a height of 30 cm. Each session was recorded by a videocamera.
The immobility time (ﬂoating while animal makes only the
necessary movements to keep the nostrils above the surface level)
was scored during 6 min (Porsolt et al., 1978). In the TST, the mice
were individually suspended by the tail 50 cm above the ﬂoor and
ﬁxed with adhesive tape placed approximately 1–2 cm from the
tip of the tail. The immobility time was recorded for 6 min (Stéru
et al., 1985).
2.5.3. ChloF antidepressant-like mechanism of action
In order to investigate a possible contribution of the 5-HT
(serotonin) system to the ChloF antidepressant-like effect, animals
(n¼8–11) were pretreated (i.p.) with PCPA (100 mg/kg, a trypto-
phan hydroxylase inhibitor) or vehicle (2% Tween 80), once a day,
for 4 consecutive days. In addition, animals were treated (p.o.)
with vehicle and ChloF 70 mg/kg, 24, 5 and 1 h before the OFT and
FST as described in Section 2.5.3. Fluoxetine 30 mg/kg was used as
positive control of serotoninergic system involvement. To investi-
gate a possible contribution of the catecholaminergic system to
the ChloF antidepressant-like effect, animals (n¼8–11) were pre-
treated (i.p.) with AMPT (100 mg/kg, a tyrosine hydroxylase
inhibitor) or vehicle (2% Tween 80) 4 h before OFT and FST. In
addition, animals were treated (p.o.) with vehicle and ChloF
70 mg/kg, 24, 5 and 1 h before the OFT and FST as described in
Section 2.5.3. Imipramine 30 mg/kg was used as positive control of
catecholaminergic system involvement.
2.5.4. Biochemical procedures
2.5.4.1. In vitro MAO assay. Three naïve mice were sacriﬁced by
cervical dislocation and the liver was removed and used as source
of crude mitochondrial pellets. The dissected tissue was washed in
ice-cold potassium phosphate buffer (0.2 M, pH 7.6) and
homogenized (Turraxs) in 40 vol 0.32 M sucrose solution in
potassium phosphate buffer. The homogenates were centrifuged
(1200 g, 7 min, 4 1C) and the supernatants collected and
centrifuged (12,500 g, 15 min, 4 1C). The pellets obtained were
centrifuged again (12,500 g, 15 min, 4 1C) in 0.32 M sucrose
solution in potassium phosphate buffer. The crude mitochondrial
pellets were suspended in 1 ml of 3.6 mM KCl solution in
potassium phosphate buffer. Protein contents of crude
mitochondrial solution were measured by the Bradford's method
(1976), with bovine serum albumin as standard. At the time of use,
the protein concentration was adjusted with phosphate buffer
(0.2 M; pH 7.6) to 0.2 mg protein per mL. The continuous
peroxidase-linked photometric assay was carried out in the 96-
well microtiter format modiﬁed from Holt et al. (1997) and
Stafford et al. (2007). To differentiate type A and B activities, the
mitochondrial fraction of mouse liver were pre-incubated with
250 nM clorgyline or pargyline at 37 1C during 5 min, respectively.
Each test well contained 120 μL amino substrate (2.5 mM
tyramine in potassium phosphate buffer), 40 μL chromogenic
solution (2 mM vanillic acid, 1 mM 4-aminoantipyrine, 8 U/ml
peroxidase in potassium phosphate buffer), 40 μL enzyme (rat
liver homogenate) and 40 μl of sample. Background wells
contained potassium phosphate buffer (0.2 M, pH 7.6) in place of
chromogenic solution. The plate was incubated at 37 1C during
30 min and read at 498 nm.
2.5.4.2. Ex vivo ELISA measurements of BDNF protein. In order to
investigate if ChloF alter BDNF protein concentration on mice
hippocampus, animals were treated (p.o.) with vehicle, ChloF
70 mg/kg and imipramine 30 mg/kg, 24, 5 and 1 h before FST.
Immediately after the behavioral test, mice were sacriﬁced by
cervical dislocation and their hippocampi dissected to BDNF ELISA
assay. After brain dissection (5–6 per group), the hippocampi were
rapidly dissected, weighed, frozen in liquid nitrogen, and stored at
80 1C. Hippocampi were suspended in 1:40 (w:v) of lysis buffer
(100 mM Tris–HCl, 1 mM NaCl, 4 mM EDTA, 2% albumin, 2% Triton-
X 100, 0.01% thimerosal, and protease inhibitors cocktail (GE Life
Sciences), pH 7.0) and homogenized using a Potter homogenizer,
the tube was submersed in an ice bath. The homogenates were
centrifuged at 16.800 g for 35 min, 4 1C, and the supernatant was
used in ELISA assay according to kit's instructions (ELISA Kit for
BDNF—Uscn Life Science Inc.s, China). Protein contents were
measured by Bradford's methods (1976), with bovine serum
albumin as standard.
2.5.5. Phytochemical screening
2.5.5.1. Thin-layer chromatography analysis (TLC). The assay of
chemical constituents presents in PEx and fractions were
performed by TLC in silica gel plates (Whatman 20 cm20 cm,
UV 254, 0.25 mm), according to procedures described by Wagner
and Bladt (1995).
2.5.5.2. Nuclear magnetic resonance (NMR). The active fraction was
analyzed by nuclear magnetic resonance (NMR) using 1H
(500 MHz) and 13C (125 MHz) and bi-dimensional techniques
Heteronuclear Multiple Quantum Correrence (HMQC) in a Bruker
spectrometer, model DRX-500 MHZ, with deutered chloroform
CDCl3 as solvent.
2.5.5.3. High performance liquid chromatography (HPLC-PDA). HPLC
of ChloF was performed on Waters equipment (Massachusetts,
USA) equipped with quaternary pump, separation module e2695,
photodiode array detector (PDA) 2998 and data processing system
Enpower 2.0. We used Phenomenex C-8 column (250 mm
4.6 mm, 5 mm) at a temperature of 25 1C. The detection system
used was monitored at 202 nm. The injection volume was 30 mL
and the run in isocratic mode, used as mobile phase acetonitrile/
water (9:1) at a constant rate of 1.0 mL/min. The maximal running
time was 40 min. Lupeol (Santa Cruz) and β-sitosterol (Sigma)
were used as reference.
2.5.6. Statistical analysis
Data were presented as mean7standard error of the mean (SEM).
Statistical analysis were done using Student's t test (control 
positive control) or by one-way ANOVA followed by Newman–Keuls'
test (control  treated groups). When appropriated two-way ANOVA
followed by Bonferroni's post-hoc test were used. Statistical difference
was set at Po0.05. All graphics were drawn using GraphPad Prisms
software version 5.0.
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3. Results
3.1. Overall effects of the treatments in the locomotor activity (OFT)
All treatment were tested in the open ﬁeld test in order to
avoid false-positive or false-negative results related to alteration in
the locomotors activity. As Table 1 shows, none of the treatments
tested in this study altered the number of areas crossed when
compared with its respective control group.
3.2. Antidepressant-like effects of crude extract and fractions
In FST, male mice treated with PEx 100, 300 and 1000 mg/kg
reduced the in immobility time (Po0.05 to all tested doses, Fig. 1);
imipramine 30 mg/kg also reduce the immobility time (Po0.001;
Fig. 1), as expected.
When the experiment was conducted with the fractions, only
the ChloF 70 mg/kg reduced the immobility time (Po0.05; Fig. 2),
whereas with the EAF 180 mg/kg was observed a tendency in
reducing this parameter (P¼0.06). Imipramine reduced the immo-
bility time (Po0.001; Fig. 2), as expected.
In an attempt to assess the ChloF dose-effect relationship, three
doses of this fraction were tested in the forced swimming test: 35,
70 and 140 mg/kg, and all doses reduced the immobility time
(Po0.05, Po0.001 and Po0.05, respectively, Fig. 3A), as well as
imipramine 30 mg/kg (Po0.001; Fig. 3A). ChloF 35, 70 mg/kg also
increased the climbing time (Po0.05 and Po0.01, respectively,
Fig. 3D). Moreover, ChloF 70 and 140 mg/kg increased the swim-
ming time (Po0.01, Fig. 3C). Imipramine 30 mg/kg also increased
the climbing (Po0.05; Fig. 3D) and swimming time (Po0.01;
Fig. 3C). This dose-effect relationship study was also observed in
the tail suspension test, where ChloF 70 and 140 mg/kg reduced
the immobility time (Po0.05, Fig. 3B), as well as imipramine
30 mg/kg (Po0.01; Fig. 3B).
3.3. Contribution of the serotonergic and catecholaminergic system
to ChloF antidepressant-like effect
Pretreatment with the 5-HT synthesis inhibitor PCPA 100 mg/
kg prevented the ﬂuoxetine 30 mg/kg (Po0.01; Fig. 4A) and ChloF
70 mg/kg antidepressant-like effects (Po0.01; Fig. 4B). Pretreat-
ment with the non-selective blocker of catecholamine synthesis
AMPT 100 mg/kg also prevented the ChloF 70 mg/kg (Po0.05;
Fig. 4D) as well as imipramine 30 mg/kg antidepressant-like
effects (Po0.01; Fig. 4C).
Table 1
Locomotor activity (number of squares crossed) in the open ﬁeld after different
pharmacological treatments.
Experimental groups Mean7SEM
Crude L. pacari extract
Vehicle 10 mL/kg p.o. 127.7710.68
PEx 100 mg/kg p.o. 147.2714.34
PEx 300 mg/kg p.o. 122.9716.79
PEx 1000 mg/kg p.o. 97.59714.93
Imipramine 30 mg/kg p.o. 108.2710.06
L. pacari extract fractions
Vehicle 10 mL/kg p.o. 108.375.07
ChloF 70 mg/kg p.o. 97.475.44
EAF 180 mg/kg p.o. 109.774.47
BuF 370 mg/kg p.o. 98.878.84
AqF 1 g/kg p.o. 100.876.91
Imipramine 30 mg/kg p.o. 97.077.07
ChloF dose effect curve
Vehicle 10 mL/kg p.o. 162.677.62
ChloF 35 mg/kg p.o. 161.278.26
ChloF 70 mg/kg p.o. 160.2711.05
ChloF 140 mg/kg p.o. 162.5712.03
Imipramine 30 mg/kg p.o. 153.779.41
Interaction of ﬂuoxetine with PCPA
Vehicle 10 mL/kg i.p.þVehicle 10 mL/kg p.o. 128.579.81
Vehicle 10 mL/kg i.p.þFluoxetine 30 mg/kg p.o. 140.077.25
PCPA 100 mg/kg i.p.þVehicle 10 mL/kg p.o. 140.8710.86
PCPA 100 mg/kg i.p.þFluoxetine 30 mg/kg p.o. 155.6710.41
Interaction of ChloF with PCPA
Vehicle 10 mL/kg i.p.þVehicle 10 mL/kg p.o. 130.0710.50
Vehicle 10 mL/kg i.p.þChloF 70 mg/kg p.o. 125.678.02
PCPA 100 mg/kg i.p.þVehicle 10 mL/kg p.o. 128.1710.59
PCPA 100 mg/kg i.p.þChloF 70 mg/kg p.o. 115.476.66
Interaction of imipramine with AMPT
Vehicle 10 mL/kg i.p.þVehicle 10 mL/kg p.o. 116.279.91
Vehicle 10 mL/kg i.p.þ Imipramine 30 mg/kg p.o. 120.976.68
AMPT 100 mg/kg i.p.þVehicle 10 mL/kg p.o. 98.5712.70
AMPT 100 mg/kg i.p.þ Imipramine 30 mg/kg p.o. 99.2710.62
Interaction of ChloF with AMPT
Vehicle 10 mL/kg i.p.þVehicle 10 mL/kg p.o. 137.079.36
Vehicle 10 mL/kg i.p.þChloF 70 mg/kg p.o. 121.6712.46
AMPT 100 mg/kg i.p.þVehicle 10 mL/kg p.o. 106.978.63
AMPT 100 mg/kg i.p.þChloF 70 mg/kg p.o. 122.278.17
ChloF and imipramine effect before BDNF assay
Vehicle 10 mL/kg p.o. 110.9710.78
ChloF 70 mg/kg p.o. 105.3712.05
Imipramine 30 mg/kg p.o. 99.3377.64
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Fig. 1. Effect of oral treatment with ethanol extract of L. pacari stem bark (PEx) at
24, 5 and 1 h before the forced swimming test (6 min), at doses of 100, 300 and
1000 mg/kg in mice. Bars represent mean7sem of total immobility time (in
seconds) of 10–12 animals. *Po0.05 compared to control group by one-way
ANOVA followed by Newman–Keuls' test (control treated groups). #Po0.05
compared to control group by Student's t test (controlpositive control). C: control
group – vehicle (2% Tween) 10 mL/kg p.o., IMI: imipramine 30 mg/kg p.o.
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Fig. 2. Effect of oral treatment with fractions from the ethanol extract of L. pacari
stem bark at 24, 5 and 1 h before the forced swimming test (6 min) in mice. Bars
represent mean7sem of total immobility time (in seconds) of 9 animals. *Po0.05
compared to control group by one-way ANOVA followed by Newman–Keuls' test
(control treated groups). #Po0.05 compared to control group by Student's t test
(controlpositive control). C: control group – vehicle (2% Tween) 10 mL/kg p.o.,
ChloF 70 mg/kg p.o. – chloroformic, EAF 180 mg/kg p.o. – ethyl acetate, BuF
370 mg/kg p.o. – n-butanol p.o. and AqF 1 g/kg p.o. – aqueous fractions, IMI:
imipramine 30 mg/kg p.o.
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Fig. 3. Effect of oral treatment with chloroformic fraction (ChloF 70 mg/kg) from ethanol extract of L. pacari stem bark at 24, 5 and 1 h before the forced swimming (A, C and
D) and tail suspension (B) tests (6 min), at doses of 35, 70 and 140 mg/kg in mice. Total immobility (A), swimming (C) and climbing (D) time in the forced swimming test and,
total immobility time in the tail suspension (B) test. Bars represent mean7sem of 9–11 animals. *Po0.05 compared to control group by one-way ANOVA followed by
Newman–Keuls' test (control treated groups). #Po0.05 compared to control group by Student's t test (controlpositive control). C: control group – vehicle (2% Tween)
10 mL/kg p.o., IMI: imipramine 30 mg/kg p.o.
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Fig. 4. Effect of pretreatment with PCPA (100 mg/kg i.p.–4 days; A and B) and AMPT (100 mg/kg i.p.—4 h; C and D) in ﬂuoxetine (FLX—30 mg/kg, p.o, 1 h; A), chloroformic
fraction (FClor—70 mg/kg, p.o., 24, 5 and 1 h, B and D), or imipramine (IMI—30 mg/kg, p.o., 1 h, C) effects on the total immobility time of forced swimming test. Bars represent
mean7sem of 8–11 animals. *Po0.05 compared to control group; and #Po0.05 compared to FLX, IMI or ChloF groups by two-way ANOVA followed by Bonferroni's test.
C: control group—vehicle (saline 0.9%) 10 mL/kg i.p.þvehicle (2% Tween) 10 mL/kg p.o.
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3.4. In vitro MAO assay
ChloF was not able to inhibit neither MAO-A nor MAO-B
enzymatic activity, assayed in vitro, whereas, as expected, both
positive controls, clorgyline—an iMAO-A, and pargyline—an iMAO-
B, were able to inhibit the MAO subtype A (IC50: 76 nM [49–
115.7 nM]) and B (IC50: 0.3 mM [0.19–0.49 mM]), respectively (data
not shown).
3.5. Ex vivo ELISA measurements of BDNF protein
Treatment with ChloF 70 mg/kg and imipramine 30 mg/kg, at
doses that reduced the immobility time (Po0.01 and Po0.001;
Fig. 5A), increased the hippocampal BDNF levels (Po0.05; Fig. 5B).
3.6. Phytochemical screening and identiﬁcation of compounds in
CholF by NMR and HPLC-PDA
Phytochemical screening of PEx and fractions had shown the
presence of tannins, steroids, triterpenes and traces of ﬂavonoids
in PEx, and the presence of steroids and triterpenes in ChloF. In the
ethyl acetate fraction were detected steroids, triterpenes and
ﬂavonoids, while in the n-butanol and aqueous fraction, only
tannins were detected.
In the TLC, in ChloF analysis was seen the presence of steroids and
triterpenes and with RF compatible with the authentic standards of
β-sitosterol, lupeol, oleanolic and ursolic acid and α-amyrin.
NMR analysis showed characteristic data for aliphatic compounds.
13CNMR and HMQC of ChloF showed chemical shifts to β-sitosterol
(C29H50O) with lupeol (C29H50O) and stigmasterol m/z¼412 Da
(C30H50O) (Mahato and Kundu, 1994; Lemes et al., 2011). The other
chemical shifts are characteristics of 1H and 13C of the aliphatic
compounds and were not conﬁrmed its structures. The analysis by
HPLC-PDA of ChloF and of authentic standards conﬁrmed the
presence of β-sitosterol and lupeol at Rt¼18.6 min and 24.7 min,
respectively. However, the presence of oleanolic and ursolic acid and
α-amyrin were not conﬁrmed.
4. Discussion
In this study, we have evaluated the effect of L. pacari in mice
forced swimming test, as well as its fractions, and the possible
involvement of monoaminergic system in the effect of the active
fraction (ChloF), and phytochemically characterized the extract
and active fraction.
FST is the most commonly behavioral predictive test used in
preclinical phase of evaluation for antidepressant potential drugs,
since it has a good predictive validity. The acute or chronic
antidepressants administration increases the time that the animal
tried to escape of this situation, thus reducing its immobility
(Porsolt et al., 1978).
Based in our previous results, where PEx reduced the immobi-
lity time on FST after 21 days of treatment but not after acute
administration (1 h) (Galdino et al., 2009), we assessed the
antidepressant-like PEx effect using the treatment protocol pro-
posed by Porsolt et al. (1978), where three injections are per-
formed at an interval of 24 h (24, 5 and 1 h prior to FST), because
this protocol is supposed to optimize the antidepressants effect on
animal predictive tests (Porsolt et al., 1978). Using this protocol
PEx reduced the immobility time in the FST, suggesting an
antidepressant-like effect.
After this initial behavioral assay, the crude extract was sub-
jected to liquid–liquid fractionation to give the chloroform (ChloF),
ethyl acetate, n-butanol and aqueous fractions. Subsequently, we
evaluated what fraction was able to better retain the neuroactive
constituents and induce the same behavioral changes observed
with the crude extract. The fractions doses were estimated based
on previous results (Galdino et al., 2009) regarding its yield after
partition. As result, the ethyl acetate fraction showed a trend in
reducing the immobility time, while the ChloF best mimicked the
PEx effect, reducing the immobility time by 22.3%, probably by
retaining a greater concentration of the constituents responsible
for the behavioral effect. Thus, we continued this study only with
this fraction, performing the dose-response relationship on the
FST and tail suspension test (TST) (Stéru et al., 1985), another
common behavioral predictive test.
Treatment with ChloF reduced the immobility time on FST at all
tested doses, and on TST at the doses of 70 and 140 mg/kg,
reinforcing our suggestion that this fraction retaining the neu-
roactive compounds, with possible antidepressant activity. Detke
et al. (1995) suggested that in rats serotonergic drugs increase
swimming, while noradrenergic drugs increase climbing time, and
this correlation are widely used in the study of the mechanism of
action of new drugs. Evaluating these parameters, swimming and
climbing, we suggest that ChloF are capable to increase serotoner-
gic and noradrenergic transmission, since that ChloF at the doses
of 70 and 140 mg/kg increased swimming and at the doses of 35
and 70 mg/kg increased climbing. Imipramine, the positive con-
trol, a serotonin and norepinephrine reuptake inhibitor, besides
the reduction in immobility, increased both swimming and climb-
ing behaviors.
However, to better infer about the possible mechanisms
involved in the behavioral changes induced by ChloF, we also
used a pharmacological approach, in which animals were pre-
treated with two drugs that deplete monoamines: p-chlorophe-
nylalanine (PCPA—100 mg/kg for 4 days- an inhibitor of the
enzyme tryptophan hydroxylase) and α-methyl-p-tyrosine
(AMPT—100 mg/kg, 4 h before - an inhibitor of tyrosine
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Fig. 5. Effect of oral treatment (24, 5 and 1 h) with chloroformic fraction (ChloF—
70 mg/kg) and imipramine (IMI—30 mg/kg) on total immobility time (in seconds)
of forced swimming test (6 min) in mice. Each group consisted of 9–10 animals
(A). Effect of these treatments on hippocampal BDNF protein levels of 5–6 animals
(randomly chosen) previously submitted to the forced swimming test (B). Bars
represent the mean7sem. *Po0.05 compared to control group by Student's t test.
C: control group – vehicle (2% Tween) 10 mL/kg p.o.
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hydroxylase), to reduce serotonin and catecholamines endogenous
levels, respectively (Machado et al., 2012, Rodrigues et al., 2002).
Pretreatment with PCPA blocked the ChloF and ﬂuoxetine
effects, whereas AMPT blocked ChloF and imipramine effects
which suggest that both endogenous serotonin as well as catecho-
lamines are involved in the behavioral changes induced by ChloF.
Because of the involvement of both catecholaminergic and ser-
otonergic pathways, we assessed whether the ChloF could act as
MAO-A inhibitors. Several medicinal plants popularly used to
improve mood have active ingredients that inhibit the of MAO-A
activity (Stafford et al., 2007). However, ChloF neither inhibit the
MAO-A nor MAO-B enzymes activity. This is an advantage since it
reduces the chances of a “cheese reaction” for ChloF.
Antidepressant drugs or antidepressant approaches, such as
electroconvulsive therapy, increases the BDNF expression, a pos-
sible common pathway by which antidepressants exert their
therapeutic effect (Nestler et al., 2002). ChloF and imipramine
increased the hippocampal BDNF protein concentration, suggest-
ing that in this fraction there are active constituents capable of
increasing the amount of BDNF, with potential to exert antide-
pressant therapeutic effects.
In the phytochemical analysis, we observed the presence of
tannins, steroids, triterpenes and traces of ﬂavonoids in the crude
extract; in the chloroform fraction only steroids and triterpenoids
were observed, whereas the ethyl acetate fraction presented
steroids, triterpenes and traces of ﬂavonoids. In the n-butanol
and aqueous fractions only tannins were detected. In the ChloF, we
had identiﬁed, for the ﬁrst time in L. pacari extracts, the presence
of triterpene lupeol and steroids β-sitosterol and stigmasterol in
the stem bark of this plant.
5. Conclusions
The ethanol:water 7:3 extract and chloroform fraction, which is
rich in triterpenes, such as lupeol, showed positive results on
rodent predictive antidepressant tests. In the active fraction, the
effect showed may be involving the endogenous monoaminergic
systems, without inhibiting the MAO-A enzyme activity. Moreover,
this fraction increased hippocampal BDNF levels, suggesting that
these fraction constituents induce neuronal neuroplasticity. For
the ﬁrst time in the literature, it was reported the presence of
lupeol and the steroids β-sitosterol and stigmasterol in the stem
bark of this plant species. These results taken together support the
tonic use in the local traditional medicine and the antidepressant-
like effects in earlier preclinical studies besides shedding more
light on the general mechanisms by which L. pacari exhibits its
antidepressant-like effects.
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